Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRTC logo PRTC
Upturn stock ratingUpturn stock rating
PRTC logo

PureTech Health PLC (PRTC)

Upturn stock ratingUpturn stock rating
$18.01
Last Close (24-hour delay)
Profit since last BUY-6.95%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: PRTC (1-star) is a SELL. SELL since 5 days. Profits (-6.95%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $53.25

1 Year Target Price $53.25

Analysts Price Target For last 52 week
$53.25 Target price
52w Low $13.3
Current$18.01
52w High $25

Analysis of Past Performance

Type Stock
Historic Profit -21.68%
Avg. Invested days 30
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 432.70M USD
Price to earnings Ratio 8.58
1Y Target Price 53.25
Price to earnings Ratio 8.58
1Y Target Price 53.25
Volume (30-day avg) 2
Beta 0.9
52 Weeks Range 13.30 - 25.00
Updated Date 07/5/2025
52 Weeks Range 13.30 - 25.00
Updated Date 07/5/2025
Dividends yield (FY) -
Basic EPS (TTM) 2.1

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 1108.33%
Operating Margin (TTM) -1530.2%

Management Effectiveness

Return on Assets (TTM) -13.1%
Return on Equity (TTM) 6.42%

Valuation

Trailing PE 8.58
Forward PE -
Enterprise Value 79399145
Price to Sales(TTM) 89.62
Enterprise Value 79399145
Price to Sales(TTM) 89.62
Enterprise Value to Revenue 17.1
Enterprise Value to EBITDA 1.97
Shares Outstanding 24025400
Shares Floating 164801187
Shares Outstanding 24025400
Shares Floating 164801187
Percent Insiders -
Percent Institutions 1.64

ai summary icon Upturn AI SWOT

PureTech Health PLC

stock logo

Company Overview

overview logo History and Background

PureTech Health PLC is a biotherapeutics company that focuses on developing medicines to treat serious diseases. Founded in 2002, it has evolved into a company building a pipeline of therapeutic candidates across a variety of modalities.

business area logo Core Business Areas

  • Therapeutics Development: Discovery and development of novel therapies, including small molecules, antibodies, and cell therapies. Focus areas include immunology, oncology, and metabolic diseases.
  • Venture Creation: Creation of new biotech companies based on its internal research and external opportunities.
  • Clinical Trials: Conducting Clinical Trials on new therapeutics.

leadership logo Leadership and Structure

PureTech Health PLC is led by a board of directors and an executive management team. The company operates with a decentralized structure, empowering its subsidiaries and venture creations.

Top Products and Market Share

overview logo Key Offerings

  • Karuna Therapeutics (acquired by Bristol Myers Squibb): Developed KarXT for schizophrenia, a novel M1/M4-preferring muscarinic agonist. Bristol Myers Squibb acquired Karuna in late 2023 for $14 billion; competes with existing antipsychotics from companies like Johnson & Johnson and AstraZeneca.
  • Vor Biopharma: Developing engineered hematopoietic stem cell (eHSC) therapies to create treatment options for patients with cancer. Competitors in the cell therapy field include Gilead and Novartis. Revenue not directly attributable to PureTech.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. Trends include personalized medicine, gene therapy, and immunotherapy.

Positioning

PureTech Health PLC positions itself as an innovator and venture creator in the biotherapeutics space, seeking to identify and develop promising therapies with significant unmet medical needs.

Total Addressable Market (TAM)

The global biopharmaceutical market is worth over $1.5 Trillion. PureTech aims to develop therapies for significant unmet needs in diseases such as cancer.

Upturn SWOT Analysis

Strengths

  • Strong track record of creating successful biotech ventures
  • Diversified portfolio of therapeutic candidates
  • Experienced management team
  • Innovative approach to drug discovery

Weaknesses

  • High reliance on success of individual portfolio companies
  • Long development timelines and high R&D costs
  • Dependence on regulatory approvals
  • Complex corporate structure

Opportunities

  • Growing demand for innovative therapies
  • Advancements in drug discovery technologies
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Clinical trial failures
  • Economic downturn impacting investment in biotech

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • BMY
  • MRK
  • VRTX
  • GILD

Competitive Landscape

PureTech Health PLC operates in a highly competitive landscape. The company's advantage lies in its venture creation model and its ability to identify and develop promising therapies. Disadvantages include dependence on regulatory approvals and long development timelines.

Major Acquisitions

Karuna Therapeutics (acquired by Bristol Myers Squibb)

  • Year: 2023
  • Acquisition Price (USD millions): 14000
  • Strategic Rationale: Bristol Myers Squibb acquired Karuna to expand its neuroscience portfolio and gain access to KarXT for schizophrenia.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the success of ventures like Karuna Therapeutics. This will need to be quantified using stock price and financial data.

Future Projections: Future growth is dependent on the progress of current therapeutic candidates and the creation of new ventures. Analyst estimates would provide quantifiable growth projections.

Recent Initiatives: Recent initiatives include advancing clinical trials for its portfolio companies and seeking strategic partnerships.

Summary

PureTech Health PLC is a biotechnology company operating under a venture creation model. It identifies and develops promising therapeutics, creating new companies focused on specific areas. Karuna's acquisition by Bristol Myers Squibb demonstrates the potential of this model, but the company faces risks associated with lengthy drug development timelines, regulatory hurdles, and dependence on the success of individual portfolio companies. Continued success requires effective management of these challenges and successful advancement of its current pipeline.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • PureTech Health PLC Investor Relations
  • SEC Filings
  • Analyst Reports
  • Industry News Sources

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About PureTech Health PLC

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2020-11-16
CEO & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 56
Full time employees 56

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.